Last10K.com

Greenlight Biosciences Holdings, Pbc (GRNA) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022

Greenlight Biosciences Holdings, Pbc

CIK: 1822691 Ticker: GRNA
Cover Page - shares
3 Months Ended
Mar. 31, 2022
May 06, 2022
Document Information [Line Items]  
Document Type10-Q 
Entity Registrant NameGreenLight Biosciences Holdings, PBC 
Amendment Flagfalse 
Entity Central Index Key0001822691 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Current Fiscal Year End Date--12-31 
Document Period End DateMar. 31, 2022 
Document Fiscal Year Focus2022 
Document Fiscal Period FocusQ1 
Entity Filer CategoryNon-accelerated Filer 
Entity Shell Companyfalse 
Entity Small Businesstrue 
Entity Interactive Data CurrentYes 
Entity Current Reporting StatusYes 
Entity Emerging Growth Companytrue 
Entity Ex Transition Periodfalse 
Entity File Number001-39894 
Entity Tax Identification Number85-1914700 
Entity Incorporation, State or Country CodeDE 
Entity Address, Address Line One200 Boston Avenue 
Entity Address, City or TownMedford 
Entity Address, State or ProvinceMA 
City Area Code617 
Local Phone Number616-8188 
Entity Address, Postal Zip Code02155 
Title of 12(b) SecurityCommon Stock, par value $0.0001 per share 
Trading SymbolGRNA 
Security Exchange NameNASDAQ 
Entity Common Stock, Shares Outstanding 123,199,202
Entity Bankruptcy Proceedings, Reporting Currenttrue 
Warrants [Member]  
Document Information [Line Items]  
Title of 12(b) SecurityWarrants, each exercisable for one share of Common Stock for $11.50 per share 
Trading SymbolGRNAW 
Security Exchange NameNASDAQ 

View differences made from one quarter to another to evaluate Greenlight Biosciences Holdings, Pbc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Greenlight Biosciences Holdings, Pbc.

Continue

Assess how Greenlight Biosciences Holdings, Pbc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Greenlight Biosciences Holdings, Pbc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover Page
Condensed Consolidated Balance Sheets (Parentheticals) (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (Parentheticals) (Unaudited)
Condensed Consolidated Statements Of Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (Unaudited)
Consolidated Statements Of Cash Flows (Parenthetical) (Unaudited)
Accrued Expenses
Accrued Expenses (Tables)
Accrued Expenses - Summary Of Accrued Expenses (Detail)
Business Combination
Business Combination (Tables)
Business Combination - Additional Information (Detail)
Business Combination - Schedule Of Number Of Shares Of Common Stock Outstanding Immediately Consummation Of Business Combination (Details)
Business Combination - Summary Of Reconciles Elements Of Business Combination (Details)
Commitments And Contingencies
Commitments And Contingencies (Details)
Commitments And Contingencies (Tables)
Commitments And Contingencies - Summary Of Future Minimum Lease Payments Under Noncancelable Operating Leases (Details)
Debt
Debt (Tables)
Debt - Additional Information (Detail)
Debt - Summary Of Future Principal Payment Of Long Term Debt (Detail)
Debt - Summary Of Interest Expense (Detail)
Debt - Summary Of Outstanding Debt (Detail)
Debt - Summary Of Outstanding Debt (Parenthetical) (Details)
Fair Value Measurements
Fair Value Measurements (Details)
Fair Value Measurements (Details) - Schedule Of Assets And Liabilities At Fair Value On A Recurring Basis
Fair Value Measurements (Details) - Schedule Of Changes In The Fair Value Of Level 3 Warrant Liabilities
Fair Value Measurements (Tables)
Grant Revenue
Grant Revenue - Additional Information (Detail)
Income Taxes
Income Taxes (Details)
License Agreement
License Agreement - Additional Information (Detail)
License And Collaboration Agreements
License And Collaboration Agreements - Additional Information (Details)
Nature Of Business And Basis Of Presentation
Nature Of Business And Basis Of Presentation (Details)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Summary Of The Computation Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders (Details)
Net Loss Per Share - Summary Of The Excluded Potential Common Stock (Details)
Property And Equipment, Net
Property And Equipment, Net (Tables)
Property And Equipment, Net - Additional Information (Detail)
Property And Equipment, Net - Summary Of Property And Equipment (Detail)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Details)
Stock-Based Compensation - Summary Of Fair Value Assumptions Of Stock Option Awards Estimated On Grant Date (Details)
Stock-Based Compensation - Summary Of Restricted Stock Activity (Details)
Stock-Based Compensation - Summary Of Stock Options Activity (Details)
Stock-Based Compensation - Summary Of Stock Options Activity (Parenthetical) (Details)
Stock-Based Compensation - Summary Of Stock-Based Compensation Expense (Details)
Stockholder's Equity (Tables)
Stockholders' Equity
Stockholders' Equity - Additional Information (Details)
Stockholders' Equity - Summary Of Legacy Redeemable Convertible Preferred Stock Authorized, Issued, And Outstanding (Details)
Stockholders' Equity - Summary Of Legacy Redeemable Convertible Preferred Stock Authorized, Issued, And Outstanding (Parenthetical) (Details)
Subsequent Events
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Summary Of Estimated Useful Lives Of Property And Equipment (Detail)
Warrants
Warrants (Tables)
Warrants - Additional Information (Details)
Warrants - Summary Of Common Stock Warrant Classified (Details)
Warrants - Summary Of Estimated Fair Value Of The Warrants (Details)
Warrants - Summary Of Roll-Forward Of The Warrants (Details)
Warrants - Summary Of Roll-Forward Of The Warrants (Parenthetical) (Details)

Material Contracts, Statements, Certifications & more

Greenlight Biosciences Holdings, Pbc provided additional information to their SEC Filing as exhibits

Ticker: GRNA
CIK: 1822691
Form Type: 10-Q Quarterly Report
Accession Number: 0000950170-22-010061
Submitted to the SEC: Mon May 16 2022 4:02:23 PM EST
Accepted by the SEC: Mon May 16 2022
Period: Thursday, March 31, 2022
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/grna/0000950170-22-010061.htm